Neonc Technologies Holdings (NTHI) EBITDA Margin (2024 - 2025)
Neonc Technologies Holdings (NTHI) posted quarterly EBITDA Margin of 79772.05% for Q1 2025, down 7616395.0% year-over-year from N/an in Q1 2024, and down 654.8% quarter-over-quarter from 10568.66% in Q4 2024.
Neonc Technologies Holdings (NTHI) EBITDA Margin (2024 - 2025) Analysis & Trends
Neonc Technologies Holdings (NTHI) has reported EBITDA Margin for 2 consecutive years, with 79772.05% the latest figure, recorded in Q1 2025.
- In Q1 2025, EBITDA Margin fell 7616395.0% year-over-year to 79772.05%; the TTM figure through Dec 2025 stood at 145637.52% (down 13703207.0% YoY), while the FY2025 annual figure was 145637.52%, down 13703207.0% from the prior year.
- EBITDA Margin eased to 79772.05% in Q1 2025 per NTHI's latest filing, from 10568.66% in the prior quarter.
- Across five years, EBITDA Margin topped out at 3608.1% in Q1 2024 and bottomed at 79772.05% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Neonc Technologies Holdings | 116.41 Mn | 116.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -79,772.05% |
| Dec 31, 2024 | -10,568.66% |
| Jun 30, 2024 | -6,400.60% |
| Mar 31, 2024 | -3,608.10% |